Cargando…
A novel serum microRNA signature to screen esophageal squamous cell carcinoma
Circulating microRNAs (miRNAs) have been used as promising diagnostic biomarkers for esophageal squamous cell carcinoma (ESCC). We performed miRNA expression profiling using quantitative reverse transcription polymerase chain reaction (qRT‐PCR) based Exiqon panels from three ESCC pools and one norma...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5269712/ https://www.ncbi.nlm.nih.gov/pubmed/28035762 http://dx.doi.org/10.1002/cam4.973 |
_version_ | 1782501046691561472 |
---|---|
author | Huang, Zebo Zhang, Lan Zhu, Danxia Shan, Xia Zhou, Xin Qi, Lian‐wen Wu, Lirong Zhu, Jun Cheng, Wenfang Zhang, Huo Chen, Yan Zhu, Wei Wang, Tongshan Liu, Ping |
author_facet | Huang, Zebo Zhang, Lan Zhu, Danxia Shan, Xia Zhou, Xin Qi, Lian‐wen Wu, Lirong Zhu, Jun Cheng, Wenfang Zhang, Huo Chen, Yan Zhu, Wei Wang, Tongshan Liu, Ping |
author_sort | Huang, Zebo |
collection | PubMed |
description | Circulating microRNAs (miRNAs) have been used as promising diagnostic biomarkers for esophageal squamous cell carcinoma (ESCC). We performed miRNA expression profiling using quantitative reverse transcription polymerase chain reaction (qRT‐PCR) based Exiqon panels from three ESCC pools and one normal control (NC) pool samples. Using qRT‐PCR, identified serum miRNAs were further confirmed in training (32 ESCC vs. 32 NCs) and testing stages (108 ESCC vs. 96 NCs). Consequently, five serum miRNAs (miR‐20b‐5p, miR‐28‐3p, miR‐192‐5p, miR‐223‐3p, and miR‐296‐5p) were significantly overexpressed in ESCC compared with NCs. The diagnostic value of the 5‐miRNA signature was validated by an external cohort (60 ESCC vs. 60 NCs). The areas under the receiver operating characteristic curve (ROC) of the 5‐miRNA signature were 0.753, 0.763, and 0.966 for the training, testing, and the external validation stages, respectively. The expression levels of the miRNAs were also determined in tissues, arterial serum, and exosomes. MiR‐20b‐5p, miR‐28‐3p, and miR‐192‐5p were significantly upregulated in ESCC tissues, while miR‐296‐5p was overexpressed in ESCC serum exosomes. In conclusion, we identified a 5‐miRNA signature in serum for the detection of ESCC. |
format | Online Article Text |
id | pubmed-5269712 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-52697122017-02-01 A novel serum microRNA signature to screen esophageal squamous cell carcinoma Huang, Zebo Zhang, Lan Zhu, Danxia Shan, Xia Zhou, Xin Qi, Lian‐wen Wu, Lirong Zhu, Jun Cheng, Wenfang Zhang, Huo Chen, Yan Zhu, Wei Wang, Tongshan Liu, Ping Cancer Med Clinical Cancer Research Circulating microRNAs (miRNAs) have been used as promising diagnostic biomarkers for esophageal squamous cell carcinoma (ESCC). We performed miRNA expression profiling using quantitative reverse transcription polymerase chain reaction (qRT‐PCR) based Exiqon panels from three ESCC pools and one normal control (NC) pool samples. Using qRT‐PCR, identified serum miRNAs were further confirmed in training (32 ESCC vs. 32 NCs) and testing stages (108 ESCC vs. 96 NCs). Consequently, five serum miRNAs (miR‐20b‐5p, miR‐28‐3p, miR‐192‐5p, miR‐223‐3p, and miR‐296‐5p) were significantly overexpressed in ESCC compared with NCs. The diagnostic value of the 5‐miRNA signature was validated by an external cohort (60 ESCC vs. 60 NCs). The areas under the receiver operating characteristic curve (ROC) of the 5‐miRNA signature were 0.753, 0.763, and 0.966 for the training, testing, and the external validation stages, respectively. The expression levels of the miRNAs were also determined in tissues, arterial serum, and exosomes. MiR‐20b‐5p, miR‐28‐3p, and miR‐192‐5p were significantly upregulated in ESCC tissues, while miR‐296‐5p was overexpressed in ESCC serum exosomes. In conclusion, we identified a 5‐miRNA signature in serum for the detection of ESCC. John Wiley and Sons Inc. 2016-12-30 /pmc/articles/PMC5269712/ /pubmed/28035762 http://dx.doi.org/10.1002/cam4.973 Text en © 2016 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Clinical Cancer Research Huang, Zebo Zhang, Lan Zhu, Danxia Shan, Xia Zhou, Xin Qi, Lian‐wen Wu, Lirong Zhu, Jun Cheng, Wenfang Zhang, Huo Chen, Yan Zhu, Wei Wang, Tongshan Liu, Ping A novel serum microRNA signature to screen esophageal squamous cell carcinoma |
title | A novel serum microRNA signature to screen esophageal squamous cell carcinoma |
title_full | A novel serum microRNA signature to screen esophageal squamous cell carcinoma |
title_fullStr | A novel serum microRNA signature to screen esophageal squamous cell carcinoma |
title_full_unstemmed | A novel serum microRNA signature to screen esophageal squamous cell carcinoma |
title_short | A novel serum microRNA signature to screen esophageal squamous cell carcinoma |
title_sort | novel serum microrna signature to screen esophageal squamous cell carcinoma |
topic | Clinical Cancer Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5269712/ https://www.ncbi.nlm.nih.gov/pubmed/28035762 http://dx.doi.org/10.1002/cam4.973 |
work_keys_str_mv | AT huangzebo anovelserummicrornasignaturetoscreenesophagealsquamouscellcarcinoma AT zhanglan anovelserummicrornasignaturetoscreenesophagealsquamouscellcarcinoma AT zhudanxia anovelserummicrornasignaturetoscreenesophagealsquamouscellcarcinoma AT shanxia anovelserummicrornasignaturetoscreenesophagealsquamouscellcarcinoma AT zhouxin anovelserummicrornasignaturetoscreenesophagealsquamouscellcarcinoma AT qilianwen anovelserummicrornasignaturetoscreenesophagealsquamouscellcarcinoma AT wulirong anovelserummicrornasignaturetoscreenesophagealsquamouscellcarcinoma AT zhujun anovelserummicrornasignaturetoscreenesophagealsquamouscellcarcinoma AT chengwenfang anovelserummicrornasignaturetoscreenesophagealsquamouscellcarcinoma AT zhanghuo anovelserummicrornasignaturetoscreenesophagealsquamouscellcarcinoma AT chenyan anovelserummicrornasignaturetoscreenesophagealsquamouscellcarcinoma AT zhuwei anovelserummicrornasignaturetoscreenesophagealsquamouscellcarcinoma AT wangtongshan anovelserummicrornasignaturetoscreenesophagealsquamouscellcarcinoma AT liuping anovelserummicrornasignaturetoscreenesophagealsquamouscellcarcinoma AT huangzebo novelserummicrornasignaturetoscreenesophagealsquamouscellcarcinoma AT zhanglan novelserummicrornasignaturetoscreenesophagealsquamouscellcarcinoma AT zhudanxia novelserummicrornasignaturetoscreenesophagealsquamouscellcarcinoma AT shanxia novelserummicrornasignaturetoscreenesophagealsquamouscellcarcinoma AT zhouxin novelserummicrornasignaturetoscreenesophagealsquamouscellcarcinoma AT qilianwen novelserummicrornasignaturetoscreenesophagealsquamouscellcarcinoma AT wulirong novelserummicrornasignaturetoscreenesophagealsquamouscellcarcinoma AT zhujun novelserummicrornasignaturetoscreenesophagealsquamouscellcarcinoma AT chengwenfang novelserummicrornasignaturetoscreenesophagealsquamouscellcarcinoma AT zhanghuo novelserummicrornasignaturetoscreenesophagealsquamouscellcarcinoma AT chenyan novelserummicrornasignaturetoscreenesophagealsquamouscellcarcinoma AT zhuwei novelserummicrornasignaturetoscreenesophagealsquamouscellcarcinoma AT wangtongshan novelserummicrornasignaturetoscreenesophagealsquamouscellcarcinoma AT liuping novelserummicrornasignaturetoscreenesophagealsquamouscellcarcinoma |